Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBT (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed EBT for 6 consecutive years, with -$4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 139.05% year-over-year to -$4.0 million, compared with a TTM value of -$29.8 million through Dec 2025, down 423.53%, and an annual FY2025 reading of -$29.8 million, down 423.53% over the prior year.
  • EBT was -$4.0 million for Q4 2025 at Cytek Biosciences, up from -$7.8 million in the prior quarter.
  • Across five years, EBT topped out at $10.3 million in Q4 2024 and bottomed at -$11.3 million in Q1 2025.
  • Average EBT over 5 years is -$2.2 million, with a median of -$2.4 million recorded in 2022.
  • The sharpest move saw EBT skyrocketed 1601.56% in 2021, then tumbled 5048.41% in 2025.
  • Year by year, EBT stood at $444000.0 in 2021, then soared by 826.58% to $4.1 million in 2022, then decreased by 0.07% to $4.1 million in 2023, then surged by 151.08% to $10.3 million in 2024, then crashed by 139.05% to -$4.0 million in 2025.
  • Business Quant data shows EBT for CTKB at -$4.0 million in Q4 2025, -$7.8 million in Q3 2025, and -$6.8 million in Q2 2025.